Liver fat, bone marrow adipose tissue and bone mineral density in children with overweight.

MAFLD adiposity bone marrow fat fraction bone mineral density hepatic fat youth

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
25 Jul 2023
Historique:
received: 26 03 2023
revised: 21 05 2023
accepted: 21 07 2023
medline: 25 7 2023
pubmed: 25 7 2023
entrez: 25 7 2023
Statut: aheadofprint

Résumé

Hepatic steatosis is associated with decreased bone mineral density (BMD). Bone marrow fat fraction (BMFF) could play a role on this relationship in children with obesity. The objectives were: (i) to examine the relationship between the lumbar spine (LS) BMFF and BMD, and (ii) to explore the mediating role of LS-BMFF on the relationship between percentage hepatic fat with LS-BMD in preadolescent children with overweight/obesity. Hepatic fat and LS-BMFF (magnetic resonance imaging) and areal LS-BMD (LS-aBMD, dual X-ray absorptiometry) were measured in 106 children (10.6 ± 1.1 years, 53.8% girls) with overweight/obesity. LS-BMFF was inversely associated with LS-aBMD (r = -0.313, P = 0.001) and directly related with percentage hepatic fat (r = 0.276, P = 0.005). LS-BMFF was significantly greater in children with than without hepatic steatosis (P = 0.003, Cohen´s d: 0.61, 95%CI -0.21 to 1.0), while no significant difference was seen between children with overweight and those with obesity (P = 0.604; Cohen's d: 0.16, 95% CI -0.21-0.55). Mediating analysis indicated that LS-BMFF is an important mediator (50%) in the association of hepatic fat with lower LS-aBMD (indirect effect: β=-0.076, 95%CI -0.143 to -0.015). These findings suggest that hepatic steatosis, rather than overall excess adiposity, is associated with greater bone marrow adipose tissue in preadolescent children with overweight/obesity, which in turn, is related to a lower BMD. Hepatic steatosis could be a potential biomarker of osteoporosis risk, and a therapeutic target for interventions that aim to reduce not only hepatic steatosis, but for those designed to improve bone health in such children.

Identifiants

pubmed: 37490040
pii: 7230624
doi: 10.1210/clinem/dgad429
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Idoia Labayen (I)

Institute for Sustainability & Food Chain Innovation (ISFOOD), Department of Health Sciences, Public University of Navarre, 31006 Pamplona, Navarre, Spain.
IdiSNA, Navarra Institute for Health Research, 31006 Pamplona, Navarre, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain.

Cristina Cadenas-Sánchez (C)

Institute for Sustainability & Food Chain Innovation (ISFOOD), Department of Health Sciences, Public University of Navarre, 31006 Pamplona, Navarre, Spain.
IdiSNA, Navarra Institute for Health Research, 31006 Pamplona, Navarre, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain.
Department of Physical Education and Sports, Faculty of Sports Science, Sport and Health University Research Institute (iMUDS), Granada, 18071, Spain.

Fernando Idoate (F)

Radiology Department, Mutua Navarra, Department of Health Sciences, Public University of Navarre, 31012 Pamplona, Navarre, Spain.

María Medrano (M)

Institute for Sustainability & Food Chain Innovation (ISFOOD), Department of Health Sciences, Public University of Navarre, 31006 Pamplona, Navarre, Spain.
IdiSNA, Navarra Institute for Health Research, 31006 Pamplona, Navarre, Spain.
Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain.

Ignacio Tobalina (I)

Department of Nuclear Medicine, University Hospital of Araba (HUA), Bioaraba Health Research Institute 01004 Vitoria-Gasteiz, Alava, Spain.
Department of Medicine, University of the Basque Country, UPV/EHU, 01006 Vitoria-Gasteiz, Spain.

Arantxa Villanueva (A)

Department of Electrical, Electronic and Communications Engineering, Smart Cities Institute, Public University of Navarre, 31006 Pamplona, Spain.

Beatriz Rodríguez-Vigil (B)

Department of Magnetic Resonance Imaging, University Hospital of Araba (HUA), Osakidetza Basque Health Service, Osatek, Bioaraba Health Research Institute, 01004 Vitoria-Gasteiz, Alava, Spain.

Natalia Álvarez de Eulate (N)

Department of Radiology, University Hospital of Navarre, 31008 Pamplona, Navarra, Spain.

Maddi Osés (M)

Institute for Sustainability & Food Chain Innovation (ISFOOD), Department of Health Sciences, Public University of Navarre, 31006 Pamplona, Navarre, Spain.
IdiSNA, Navarra Institute for Health Research, 31006 Pamplona, Navarre, Spain.

Rafael Cabeza (R)

Department of Electrical, Electronic and Communications Engineering, Smart Cities Institute, Public University of Navarre, 31006 Pamplona, Spain.

Classifications MeSH